ABSTRACT
Krüppel-like factor 1 (KLF1/EKLF) is a transcription factor that globally activates genes involved in erythroid cell development. Various mutations are identified in the human KLF1 gene. The E325K mutation causes congenital dyserythropoietic anemia (CDA) type IV, characterized by severe anemia and non-erythroid-cell-related symptoms. The CDA mutation is in the second zinc finger of KLF1 at a position functionally involved in its interactions with DNA. The molecular parameters of how CDA-KLF1 exerts its biological effects have not been addressed. Here, using an in vitro selection strategy, we determined the preferred DNA-binding site for CDA-KLF1. Binding to the deduced consensus sequence is supported by in vitro gel shifts and by in vivo functional reporter gene studies. Two significant changes compared to wild-type (WT) binding are observed: G is selected as the middle nucleotide, and the 3′ portion of the consensus sequence is more degenerate. As a consequence, CDA-KLF1 did not bind the WT consensus sequence. However, activation of ectopic sites is promoted. Continuous activation of WT target genes occurs if they fortuitously contain the novel CDA site nearby. Our findings provide a molecular understanding of how a single mutation in the KLF1 zinc finger exerts effects on erythroid physiology in CDA type IV.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
ACKNOWLEDGMENTS
We are grateful to Barbara Imiolczyk (Inst. of Bioorganic Chemistry, PAS) for help with protein purification, to Alexey Bryzgalov and Izabela Makalowska from Adam Mickiewicz University (AMU) for help with bioinformatics analyses, to Anna Witucka (AMU), Jacek Stepniewski, Alicja Jozkowicz, and Jozef Dulak (Jagiellonian University, Krakow) for help with generation of stable cell lines, and to the Molecular Biology Techniques Laboratory (AMU) for NGS.
This work was supported by the Polish National Science Center 2013/09/B/NZ1/01879 to M.S. and by the National Institutes of Health DK046865 to J.J.B.
We declare that we have no conflicts of interest.